The Laboratory of Adaptive Immunity and Homeostasis enters a strategic research collaboration with a leading pharmaceutical company

Press release – 28 Feb 2023

Jan Terje Andersen

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen, at Oslo University Hospital and University of Oslo, is at the forefront of studies on how a broadly expressed receptor named the neonatal Fc receptor (FcRn) acts as regulator of albumin and IgG antibody transport at different body sites.

The research group has signed a framework agreement with Roche Diagnostics GmbH and entered a research collaboration with the aim to gain a deeper understanding on how FcRn-targeted molecules are handled in both in vitro and in vivo systems.

Jan Terje Andersen commented :
“Our laboratory is studying complex biology - knowledge that can translate into design of biologics with favorable binding and transport properties. We are excited to extend our collaboration with a leading company in the global biotech industry and antibody space with unique expertise and a drive to develop and translate innovative solutions into tailored products to meet the patient’s needs”.

The agreement has been negotiated by Inven2.

Collaborator Tilman Schlothauer, Senior Principal Scientist at Roche Innovation Center, gave a talk about academic-industrial collaboration at the seminar ““Bridging groundbreaking research with research-based innovation – the value of industrial collaboration in academia and commercialization”, which was held 27th October last year in Oslo Science Park. Photo: The Laboratory of Adaptive Immunity and Homeostasis.


Article (in Norwegian) on how academia and industry can enter into closer cooperation to develop new medicines:
Fra idé til implementering

For more information about the laboratory, please visit:

The Laboratory of Adaptive Immunity and Homeostasis, headed by Jan Terje Andersen

Twitter: @Andersen JT

Page visits: 2597